Psoriasis

Psoriasis is a chronic, immune-mediated inflammatory disease characterized by accelerated keratinocyte turnover, erythematous plaques, and systemic immune dysregulation. Far beyond a superficial skin condition, psoriasis is increasingly recognized as a multisystem disorder associated with metabolic syndrome, cardiovascular risk, and psychological burden. As a major therapeutic and research focus at every global Dermatology Conference, this session explores the evolving understanding of immunologic pathways, biologic therapies, and comprehensive disease management. Closely aligned with chronic inflammatory skin disease management, psoriasis care now integrates molecular targeting, lifestyle modification, and long-term monitoring.

The session begins with an exploration of the immunopathogenesis of psoriasis, highlighting the role of T-helper 17 cells, interleukin-23 signaling, and tumor necrosis factor-alpha in driving epidermal hyperproliferation. This cytokine cascade leads to thickened plaques, scaling, and characteristic silvery lesions commonly affecting the scalp, elbows, knees, and lower back.

Clinical phenotypes—including plaque, guttate, pustular, and erythrodermic psoriasis—are reviewed with emphasis on differential diagnosis and severity assessment tools such as PASI scoring. Nail involvement and scalp disease are discussed as predictors of systemic progression. Early identification of psoriatic arthritis risk factors remains critical for preventing joint damage.

Therapeutic strategies have expanded dramatically in recent years. Topical corticosteroids and vitamin D analogues remain foundational for mild disease, while systemic agents and targeted biologics offer transformative outcomes for moderate to severe cases. The session explores IL-17 and IL-23 inhibitors, highlighting their mechanism of action and long-term safety data.

Lifestyle factors, including obesity, smoking, and stress, are recognized as modulators of disease severity. Integrative management incorporating weight optimization and stress reduction supports sustained remission. Patient counseling addresses adherence challenges and psychosocial impact, as visible plaques may significantly affect self-esteem and quality of life.

Emerging research into personalized medicine and biomarker-guided therapy selection continues to refine psoriasis care. By combining immunologic insight with comprehensive patient-centered strategies, this session equips dermatologists to deliver precise, long-term disease control.